Abstract:PURPOSE: Non-interventional study in outpatient, contrast-enhanced CT; 1. to determine the extent of preventive measures for risk reduction of adverse drug reactions after contrast-enhanced CT examinations. 2. to prospectively determine the incidence and severity of adverse drug reactions occurring after administration of the iso-osmolar contrast medium iodixanol. 3. to determine a possible influence of preventive measures on the incidence/severity of adverse drug reactions..MATERIALS AND METHODS: Evaluable documentation was provided for 9953 patients from 66 radiology centers across Germany. Patient characteristics, aspects of iodixanol administration, and adverse events with an at least "possible" relationship were documented on a standardized case report form (CRF) and were evaluated up to seven days after contrast medium administration.RESULTS: About 55.5 % of patients showed one or more risk factors (e. g. impaired renal function 4.4 %, diabetes mellitus 8.5 %, hypertension 20.6 %). One third of the sites did not implement any preventive measures. Patients with a known risk for an allergy-like reaction were more likely to receive pharmacologic preventive treatment (0.5 - 50.5 %). Oral hydration was the main preventive measure in patients with renal risk factors (< 8 %) followed by intravenous hydration (1 %). Adverse drug reactions, mainly hypersensitivity reactions, occurred in 77 patients (0.74 %), but were classified as serious in only 3 patients (0.03 %). No statistically significant correlation between risk factors, preventive measures, and adverse reactions could be found.CONCLUSION: The use of preventive measures for CT examinations in this outpatient setting was generally low with risk patients being pre-medicated more often, depending on their history. In the routine outpatient setting, iso-osmolar iodixanol was very well tolerated in almost 10,000 patients undergoing diagnostic CT. The rate of acute and delayed adverse reactions was low. No correlation could be found between risk factors, preventive measures and the incidence of adverse drug reactions.KEY POINTS: • Rare use of preventive measures for outpatient CT examinations.• Low rate of acute and late adverse drug reactions to iodixanol.• No correlation between risk factors, preventive measures and adverse drug reactions.

Safety and efficacy of domestic iodixanol injection in interventional neuroradiology:a multicenter clinical trial

Clinical effectiveness of contrast medium injection protocols for 80-kV coronary and craniocervical CT angiography—a prospective multicenter observational study

An Open Label, Prospective, Multicenter, Non-Interventional Study of Iodixanol 270 Mg I/mL for Use in Individuals Undergoing Computed Tomography Angiography in Real-World Clinical Practice.

Renal Tolerability of Iopromide and Iodixanol in 562 Renally Impaired Patients Undergoing Cardiac Catheterisation: the Direct Study

Comparison of Safety and Diagnostic Efficacy of Iohexol 240 mgI/mL, Iopamidol 250 mgI/mL, and Iodixanol 270 mgI/mL in Cerebral Angiography: A Prospective, Multicenter Study

Comparison in myelography between iodixanol 270 and 320 mgI/ml and iotrolan 300 mgI/ml: a multicentre, randomised, parallel-group, double-blind, phase III trial

Post-Marketing Surveillance of the Safety Profile of Iodixanol in the Outpatient CT Setting: A Prospective, Multicenter, Observational Study of Patient Risk Factors, Adverse Reactions and Preventive Measures in 9953 Patients

Renal adverse effect of intravenous administration of iodixanol (270mg I/ml)

Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial

Feasibility of low dose Iso-osmolar Contrast Media in 640-slice Volume CT Coronary Angiography

Significant perturbation in renal functional magnetic resonance imaging parameters and contrast retention for iodixanol compared with iopromide: an experimental study using blood-oxygen-level-dependent/diffusion-weighted magnetic resonance imaging and computed tomography in rats.

Adverse Reactions of Iodixanol (270mg I/mL) in Coronary CT Angiography

Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial

High-volume Nonionic Dimeric Contrast Medium: First Experiences During Complex Coronary Interventions

Significant Perturbation in Renal Functional Magnetic Resonance Imaging Parameters and Contrast Retention for Iodixanol Compared with Iopromide

Clinically useful dilution factors for iodine and gadolinium contrast material: an animal model of pediatric digital subtraction angiography using state-of-the-art flat-panel detectors

A multicenter prospective registration study of iodixanol in the treatment of major adverse cardiovascular and cerebrovascular events and contrast-induced acute kidney injury, in Chinese patients with chronic kidrey disease undergoing percutaneous coronary intervention

Effects of a High Dose of the Contrast Medium Iodixanol on Renal Function in Patients Following Percutaneous Coronary Intervention

Analysis of iodixanol-induced delayed hypersensitive reactions in patients undergoing digital subtraction angiography

Retrospective analysis of non-laboratory-based adverse drug reactions induced by intravenous radiocontrast agents in a Joint Commission International-accredited academic medical center hospital in China

Personalized Application of Three Different Concentrations of Iodinated Contrast Media in Coronary Computed Tomography Angiography.